AU2002221873A1 - Epothilone resistant cell lines - Google Patents
Epothilone resistant cell linesInfo
- Publication number
- AU2002221873A1 AU2002221873A1 AU2002221873A AU2187302A AU2002221873A1 AU 2002221873 A1 AU2002221873 A1 AU 2002221873A1 AU 2002221873 A AU2002221873 A AU 2002221873A AU 2187302 A AU2187302 A AU 2187302A AU 2002221873 A1 AU2002221873 A1 AU 2002221873A1
- Authority
- AU
- Australia
- Prior art keywords
- cell lines
- resistant cell
- epothilone resistant
- epothilone
- lines
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Abandoned
Links
Classifications
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
- G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
- G01N33/5011—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics for testing antineoplastic activity
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
- A61K47/6801—Drug-antibody or immunoglobulin conjugates defined by the pharmacologically or therapeutically active agent
- A61K47/6803—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
- A61K47/6835—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site
- A61K47/6851—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a determinant of a tumour cell
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
- C12N5/06—Animal cells or tissues; Human cells or tissues
- C12N5/0602—Vertebrate cells
- C12N5/0693—Tumour cells; Cancer cells
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
- G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
- G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
- G01N33/5014—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics for testing toxicity
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2503/00—Use of cells in diagnostics
- C12N2503/02—Drug screening
Landscapes
- Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Life Sciences & Earth Sciences (AREA)
- Biomedical Technology (AREA)
- Immunology (AREA)
- Chemical & Material Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Health & Medical Sciences (AREA)
- Molecular Biology (AREA)
- Hematology (AREA)
- Urology & Nephrology (AREA)
- Medicinal Chemistry (AREA)
- Biotechnology (AREA)
- Cell Biology (AREA)
- Microbiology (AREA)
- Biochemistry (AREA)
- Toxicology (AREA)
- Pathology (AREA)
- Analytical Chemistry (AREA)
- Physics & Mathematics (AREA)
- Food Science & Technology (AREA)
- General Physics & Mathematics (AREA)
- Tropical Medicine & Parasitology (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Organic Chemistry (AREA)
- Epidemiology (AREA)
- Genetics & Genomics (AREA)
- Zoology (AREA)
- Wood Science & Technology (AREA)
- General Engineering & Computer Science (AREA)
- Oncology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US25270600P | 2000-11-22 | 2000-11-22 | |
US60/252,706 | 2000-11-22 | ||
PCT/EP2001/013442 WO2002042432A2 (en) | 2000-11-22 | 2001-11-20 | Epothilone resistant cell lines |
Publications (1)
Publication Number | Publication Date |
---|---|
AU2002221873A1 true AU2002221873A1 (en) | 2002-06-03 |
Family
ID=22957167
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
AU2002221873A Abandoned AU2002221873A1 (en) | 2000-11-22 | 2001-11-20 | Epothilone resistant cell lines |
Country Status (5)
Country | Link |
---|---|
US (2) | US20040038324A1 (ja) |
EP (1) | EP1363996A2 (ja) |
JP (1) | JP2004514433A (ja) |
AU (1) | AU2002221873A1 (ja) |
WO (1) | WO2002042432A2 (ja) |
Families Citing this family (12)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US6867305B2 (en) | 1996-12-03 | 2005-03-15 | Sloan-Kettering Institute For Cancer Research | Synthesis of epothilones, intermediates thereto and analogues thereof |
DE69734362T2 (de) * | 1996-12-03 | 2006-07-20 | Sloan-Kettering Institute For Cancer Research | Synthese von epothilonen, zwischenprodukte dazu, analoga und verwendungen davon |
US20020058286A1 (en) * | 1999-02-24 | 2002-05-16 | Danishefsky Samuel J. | Synthesis of epothilones, intermediates thereto and analogues thereof |
US7649006B2 (en) | 2002-08-23 | 2010-01-19 | Sloan-Kettering Institute For Cancer Research | Synthesis of epothilones, intermediates thereto and analogues thereof |
DK1767535T3 (da) * | 2002-08-23 | 2010-04-12 | Sloan Kettering Inst Cancer | Syntese af epothiloner, mellemprodukter deraf, analoge og deres anvendelse |
EP2634252B1 (en) | 2005-02-11 | 2018-12-19 | University of Southern California | Method of expressing proteins with disulfide bridges |
US20090275070A1 (en) * | 2005-11-23 | 2009-11-05 | Housey Gerard M | Compounds and Methods of Identifying, Synthesizing, Optimizing and Profiling Protein Modulators |
WO2007130501A2 (en) * | 2006-05-01 | 2007-11-15 | University Of Southern California | Combination therapy for treatment of cancer |
US8802394B2 (en) | 2008-11-13 | 2014-08-12 | Radu O. Minea | Method of expressing proteins with disulfide bridges with enhanced yields and activity |
JP2013524836A (ja) | 2010-04-25 | 2013-06-20 | マウント・シナイ・スクール・オブ・メディスン | 多能性細胞からの前部前腸内胚葉の生成 |
JP5881254B2 (ja) | 2010-05-18 | 2016-03-09 | セルリアン・ファーマ・インコーポレイテッド | 自己免疫疾患およびその他の疾患の治療のための組成物および方法 |
JP5776144B2 (ja) * | 2010-07-22 | 2015-09-09 | 株式会社島津製作所 | チューブリン除去された無細胞系タンパク質合成用細胞抽出液の調製方法、無細胞系タンパク質合成用試薬キット及び無細胞系タンパク質合成方法 |
Family Cites Families (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5489519A (en) * | 1992-10-27 | 1996-02-06 | Queen's University At Kingston | Multidrug resistance protein |
-
2001
- 2001-11-20 AU AU2002221873A patent/AU2002221873A1/en not_active Abandoned
- 2001-11-20 WO PCT/EP2001/013442 patent/WO2002042432A2/en active Search and Examination
- 2001-11-20 JP JP2002545138A patent/JP2004514433A/ja active Pending
- 2001-11-20 US US10/432,072 patent/US20040038324A1/en not_active Abandoned
- 2001-11-20 EP EP01997543A patent/EP1363996A2/en not_active Withdrawn
-
2007
- 2007-01-05 US US11/650,375 patent/US20070134744A1/en not_active Abandoned
Also Published As
Publication number | Publication date |
---|---|
US20040038324A1 (en) | 2004-02-26 |
JP2004514433A (ja) | 2004-05-20 |
US20070134744A1 (en) | 2007-06-14 |
WO2002042432A2 (en) | 2002-05-30 |
WO2002042432A3 (en) | 2003-10-02 |
EP1363996A2 (en) | 2003-11-26 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
AU2001262847A1 (en) | Language-understanding | |
AU2001292739A1 (en) | 1-oxorapamycins | |
AU2001254546A1 (en) | Aminopiperidines | |
AU2000267458A1 (en) | Hypercomputer | |
AU2001239310A1 (en) | Decahydro-isoquinolines | |
AU2001220246A1 (en) | Neckphone | |
AU2002211620A1 (en) | Autoanastomosis | |
AU2001258349A1 (en) | Bisacylguanidine | |
AU2001296577A1 (en) | Chlorophyllases | |
AU2001279754A1 (en) | Indoloquinazolinones | |
AU2002220553A1 (en) | Bioreactor | |
AU2002211128A1 (en) | Step-bike | |
AU2001285886A1 (en) | 2-guanidino-4-aryl-quinazoline | |
AU2001290931A1 (en) | Ski-snowboard | |
AU2002221873A1 (en) | Epothilone resistant cell lines | |
AU2001293852A1 (en) | Sulfonylguanidine | |
AU2001258924A1 (en) | Microsatellite-aflp | |
AU2002226346A1 (en) | 2-aryl-5-trifluoromethylpyridines | |
AU2001281921A1 (en) | Bdellosomes | |
AU2001262263A1 (en) | Line arrangement | |
AU2001246864A1 (en) | Hypotensors | |
AU2001291876A1 (en) | Triazolo-epothilones | |
AU2002214354A1 (en) | Neck-phone | |
AU4620300A (en) | Can | |
AU2001295713A1 (en) | Blast-processing |